Burden and detriment of drug-resistant tuberculosis in children

doi:10.3969/j.issn.1000-6621.2018.09.016

Abstract

Abstract:

Drug-resistant tuberculosis is one of the major health problems in children. Due to the difficulties in diagnosis, low detection rate, low cure rate and high transmission rate, drug-resistant tuberculosis is a critical problem for pediatricians and tuberculosis prevention and control experts. The authors collected and reviewed domestic and international data on the burden and danger of drug-resistant tuberculosis in children to understand status of drug-resistant tuberculosis in children and timely solve the current problems.

Key words: Tuberculosis, multidrug-resistant, Child, Cost of illness, Risk assessment, Review

Jie-qiong LI,A-dong SHEN. Burden and detriment of drug-resistant tuberculosis in children[J]. Chinese Journal of Antituberculosis, 2018, 40(9): 989-992. doi: 10.3969/j.issn.1000-6621.2018.09.016

References 30

[1]	World Health Organization. The end TB strategy: global strategy and targets for tuberculosis prevention, care and control after 2015. Geneva: World Health Organization, 2015.
[2]	World Health Organization. Global tuberculosis report 2017. Geneva: World Health Organization, 2017.
[3]	Jenkins HE, Tolman AW, Yuen CM , et al. Incidence of multidrug-resistant tuberculosis disease in children: systematic review and global estimates. Lancet, 2014,383(9928):1572-1579. doi: 10.1016/S0140-6736(14)60195-1 URL
[4]	Jenkins HE, Yuen CM . The burden of multidrug-resistant tuberculosis in children. Int J Tuberc Lung Dis, 2018,22(5):3-6. doi: 10.5588/ijtld.17.0357 URL pmid: 29665947
[5]	Dodd PJ, Sismanidis C, Seddon JA . Global burden of drug-resistant tuberculosis in children: a mathematical modeling study. Lancet Infect Dis, 2016,16(10):1193-1201. doi: 10.1016/S1473-3099(16)30132-3 URL
[6]	Zignol M, Sismanidis C, Falzon D , et al. Multidrug-resistant tuberculosis in children: evidence from global surveillance. Eur Respir J, 2013,42(3):701-707. doi: 10.1183/09031936.00175812 URL pmid: 3759300
[7]	Macías Parra M, Kumate Rodríguez J, Arredondo García JL , et al. Mycobacterium tuberculosis Complex Genotype Diversity and Drug Resistance Profiles in a Pediatric Population in Mexico. Tuberc Res Treat, 2011,2011:239042.
[8]	Fairlie L, Beylis NC, Reubenson G , et al. High prevalence of childhood multi-drug resistant tuberculosis in Johannesburg, South Africa: a cross sectional study. BMC Infect Dis, 2011,11:28. doi: 10.1186/1471-2334-11-28 URL
[9]	Kim HJ, Yoon HH, Eun BW , et al. The Rate of Drug-Resis-tant Tuberculosis in Korean Children and Adolescents Since 2007. J Korean Med Sci, 2017,32(6):954-960. doi: 10.3346/jkms.2017.32.6.954 URL pmid: 28480653
[10]	全国第五次结核病流行病学抽样调查技术指导组, 全国第五次结核病流行病学抽样调查办公室. 2010年全国第五次结核病流行病学抽样调查报告. 中国防痨杂志, 2012,34(8):485-508.
[11]	Jiao WW, Liu ZG, Han R , et al. Prevalence of drug resistant Mycobacterium tuberculosis among children in China. Tuberculosis (Edinb), 2015,95(3):315-320. doi: 10.1016/j.tube.2015.02.041 URL pmid: 25814302
[12]	彭哲, 刘芮汐, 李奇志 , 等. 儿童结核病耐药状况及危险因素分析. 中国微生态学杂志, 2011,23(7):644-646.
[13]	Tao NN, He XC, Zhang XX , et al. Drug-Resistant Tuberculosis among Children, China, 2006-2015. Emerg Infect Dis, 2017,23(11):1800-1805. doi: 10.3201/eid2311.170234 URL pmid: 29047424
[14]	World Health Organization. Guidance for national tuberculosis programmes on the management of tuberculosis in children. Second Edition. Geneva: World Health Organization, 2014. URL pmid: 17131777
[15]	Falzon D, Schünemann HJ, Harausz E , et al. World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update. Eur Respir J, 2017, 49(3). pii: 1602308. doi: 10.1183/13993003.02308-2016 URL pmid: 5399349
[16]	Hire R, Kale AS, Dakhale GN , et al. A prospective, observational study of adverse reactions to drug regimen for multi-drug resistant pulmonary tuberculosis in central India. Mediterr J Hematol Infect Dis, 2014,6(1):e2014061. doi: 10.4084/mjhid.2014.061 URL
[17]	Bhushan B, Chander R, Kajal NC , et al. Profile of adverse drug reactions in drug resistant tuberculosis from Punjab. Indian J Tuberc, 2014,61(4):318-324. URL pmid: 25675695
[18]	王飞, 陈彬, 周琳 , 等. 耐多药肺结核患者抗结核药物所致不良反应发生情况. 中华传染病杂志, 2017,35(2):83-87.
[19]	Mukherjee A, Lodha R, Kabra SK . Current therapies for the treatment of multidrug-resistant tuberculosis in children in India. Expert Opin Pharmacother, 2017,18(15):1595-1606. doi: 10.1080/14656566.2017.1373090 URL
[20]	Hall EW, Morris SB, Moore BK , et al. Treatment Outcomes of Children With HIV Infection and Drug-resistant TB in Three Provinces in South Africa, 2005-2008. Pediatr Infect Dis J, 2017,36(12):e322-e327. doi: 10.1097/INF.0000000000001691 URL
[21]	Chiang SS, Starke JR, Miller AC , et al. Baseline Predictors of Treatment Outcomes in Children With Multidrug-Resistant Tuberculosis: A Retrospective Cohort Study. Clin Infect Dis, 2016,63(8):1063-1071. doi: 10.1093/cid/ciw489 URL
[22]	Ködmön C, van den Boom M, Zucs P , et al. Childhood multidrug-resistant tuberculosis in the European Union and Euro-pean Economic Area: an analysis of tuberculosis surveillance data from 2007 to 2015. Euro Surveill, 2017,22(47). doi: 10.2807/1560-7917.ES.2017.22.47.17-00103.
[23]	Ettehad D, Schaaf HS, Seddon JA , et al. Treatment outcomes for children with multidrug-resistant tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis, 2012,12(6):449-456. doi: 10.1016/S1473-3099(12)70033-6 URL
[24]	廖琼, 谭珊, 朱渝 , 等. 儿童耐药结核病的临床特点及二线抗结核治疗效果分析. 中华儿科杂志, 2017,55(2):100-103.
[25]	王雪静, 武桂英, 龚幼龙 , 等. 结核病控制项目地区耐药结核病病人经济负担研究. 中国卫生经济, 2005,24(3):49-51.
[26]	Yang C, Luo T, Shen X , et al. Transmission of multidrug-resistant Mycobacterium tuberculosis in Shanghai, China: a re-trospective observational study using whole-genome sequencing and epidemiological investigation. Lancet Infect Dis, 2017,17(3):275-284. doi: 10.1016/S1473-3099(16)30418-2 URL
[27]	Shah NS, Auld SC, Brust JC , et al. Transmission of Extensively Drug-Resistant Tuberculosis in South Africa. N Engl J Med, 2017,376(3):243-253. doi: 10.1056/NEJMoa1604544 URL pmid: 28099825
[28]	Meftahi N, Namouchi A, Mhenni B , et al. Evidence for the critical role of a secondary site rpoB mutation in the compensatory evolution and successful transmission of an MDR tuberculosis outbreak strain. J Antimicrob Chemother, 2016,71(2):324-332. doi: 10.1093/jac/dkv345 URL
[29]	Comas I, Borrell S, Roetzer A , et al. Whole-genome sequencing of rifampicin-resistant Mycobacterium tuberculosis strains identifies compensatory mutations in RNA polymerase genes. Nat Genet, 2012,44(1):106-110. doi: 10.1038/ng.1038 URL
[30]	Li QJ, Jiao WW, Yin QQ , et al. Compensatory Mutations of Rifampin Resistance Are Associated with Transmission of Multidrug-Resistant Mycobacterium tuberculosis Beijing Genotype Strains in China. Antimicrob Agents Chemother, 2016,60(5):2807-2812. doi: 10.1128/AAC.02358-15 URL